After painting a poor safety profile, Pfizer and Eli Lilly are shooting for a new pain drug OK anyway

Months after analysts wrote off the NGF pain drug tanezumab as a perpetual loser, Pfizer and Eli Lilly have decided to push ahead and see if they can’t squeeze past the FDA with the low-dose version of this therapy.